Results 11 to 20 of about 60,579 (143)

Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment.

PLoS ONE, 2011
Murine monoclonal antibody V5B2 which specifically recognizes the pathogenic form of the prion protein represents a potentially valuable tool in diagnostics or therapy of prion diseases. As murine antibodies elicit immune response in human, only modified
Nives Skrlj, Tanja Vranac, Mara Popović, Vladka Curin Šerbec, Marko Dolinar   +4 more
doaj   +1 more source

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Nature Communications, 2021
Here, the authors identify and characterize two mouse-derived monoclonal antibodies against SARS-CoV-2 spike protein that target different epitopes in RBD and block the interaction S/ACE2 and show that a formulated humanized version cocktail exhibits ...
Chao Zhang, Yifan Wang, Yuanfei Zhu, Caixuan Liu, Chenjian Gu, Shiqi Xu, Yalei Wang, Yu Zhou, Yanxing Wang, Wenyu Han, Xiaoyu Hong, Yong Yang, Xueyang Zhang, Tingfeng Wang, Cong Xu, Qin Hong, Shutian Wang, Qiaoyu Zhao, Weihua Qiao, Jinkai Zang, Liangliang Kong, Fangfang Wang, Haikun Wang, Di Qu, Dimitri Lavillette, Hong Tang, Qiang Deng, Youhua Xie, Yao Cong, Zhong Huang   +29 more
doaj   +1 more source

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Nature Communications, 2022
Despite effective vaccines against SARS-CoV-2, therapeutic options such as anti-virals and neutralizing antibodies are critical in treating disease, especially given the breakthrough infections of emerging VOCs. Here, Peng et al.
Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese Tripler, Lupeng Ye, Ryan D. Chow, Zhenhao Fang, Chunxiang Wu, Matthew B. Dong, Matthew Cook, Guilin Wang, Paul Clark, Bryce Nelson, Daryl Klein, Richard Sutton, Michael S. Diamond, Craig B. Wilen, Yong Xiong, Sidi Chen   +23 more
doaj   +1 more source

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

Clinical and Developmental Immunology, 2013
Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (
Marcello Lanari, Silvia Vandini, Santo Arcuri, Silvia Galletti, Giacomo Faldella   +4 more
doaj   +1 more source

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

Antibodies, 2019
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole ...
Erik Doevendans, Huub Schellekens
doaj   +1 more source

Functional epitopes and neutralizing antibodies of vaccinia virus

Frontiers in Microbiology, 2023
Smallpox is an infectious disease caused by the variola virus, and it has a high mortality rate. Historically it has broken out in many countries and it was a great threat to human health.
Fenghao Peng, Naijing Hu, Yingjun Liu, Cong Xing, Longlong Luo, Xinying Li, Jing Wang, Guojiang Chen, He Xiao, Chenghua Liu, Beifen Shen, Jiannan Feng, Chunxia Qiao   +12 more
doaj   +1 more source

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45

Nature Communications, 2018
Malaria protein Pfs48/45 is a promising transmission-blocking antigen targeted by antibodies. Here, the authors determine the structure of its transmission-blocking epitope I, and generate a humanized monoclonal antibody that binds Pfs48/45 with high ...
Prasun Kundu, Anthony Semesi, Matthijs M. Jore, Merribeth J. Morin, Virginia L. Price, Alice Liang, Jingxing Li, Kazutoyo Miura, Robert W. Sauerwein, C. Richter King, Jean-Philippe Julien   +10 more
doaj   +1 more source

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

BioTechniques, 2020
Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future ...
Liaqat Ali, Gauri Saxena, Meleri Jones, Georgia R Leisegang, Luke Gammon, Sharmilee Gnanapavan, Gavin Giovannoni, Klaus Schmierer, David Baker, Angray S Kang   +9 more
doaj   +1 more source

Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma

Cellular Physiology and Biochemistry, 2013
Background: Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%.
Haifeng Zhang, Liping Song, Hongtu Ye, Lide Hu, Wenlu Liang, Datao Liu   +5 more
doaj   +1 more source

Novel humanized monoclonal antibodies against ROR1 for cancer therapy

Molecular Cancer
Background Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for
Rong Wei, Xun Liao, Jiao Li, Xiaoyu Mu, Yue Ming, Yong Peng   +5 more
doaj   +1 more source